Embrace
the evidence.

We have embraced a data-driven approach to the development of the DETOUR™ System.

PTAB with the DETOUR System is clinically proven to be a safe and effective treatment for patients with long complex SFA disease.

The DETOUR2 Study is a prospective, single-arm, multicenter, international clinical investigation to evaluate the safety and effectiveness of the DETOUR System.

CLINICALLY DEMONSTRATED IN PATIENTS WITH UNMET NEEDS:

0 cm

mean
lesion length¹

0 %

chronic total occlusion before the DETOUR System¹

0 %

of enrolled patients had in-stent-restenosis¹

0 %

had previous peripheral intervention¹

Clinical evidence demonstrates PTAB using the DETOUR System is a safe and effective treatment option for patients with long complex SFA disease.

DEMONSTRATED EFFICACY

0 %

freedom from
CD-TLR at 2 years³

0 %

freedom from 100%
occlusion at 2 years³

0 %

clinical success*
at 2 years⁴

DEMONSTRATED SAFETY

0 %

infection rate
at 30 days³

0 %

freedom from major adverse events at 30 days¹

0 %

DVT rate at
30 days¹

MINIMAL HOSPITAL STAYS

0 DAY

average hospital stay
post-procedure³

*Clinical success is defined as an improvement in limb ischemia with a scale increase of ≥1 according to the Rutherford Classification.

Be one of the first to try PTAB with the DETOUR System

Contact Us:

First Name

Last Name

State

City

Postal Code

Country

Speciality

Message

If you are human, leave this field blank.

I want to explore further:

DETOUR System Downloads:

Other Links:

News

Videos

For information on Endologix’s privacy practices, see our Privacy Statement

REFERENCES

Lyden. Percutaneous Bypass for Treatment of Long-Segment Femoropopliteal Disease: 12 Month Results from the DETOUR 2 Trial Volume 75, Issue 6, E337-E338, June 2022
P220021 Summary of Safety and Effectiveness Data (SSED). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm
Lyden et al. Durability of Percutaneous Bypass for Treatment of Femoropopliteal Disease: Two-year Outcomes of the DETOUR-2 Study. VAM 2023
The DETOUR System IFU 117 Rev A

Legal Information:

INDICATIONS FOR USE:
The DETOURTM System is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200mm to 460mm in length with chronic total occlusions (100mm to 425mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOURTM System, or any of its components, is not for use in the coronary and cerebral vasculature.

CONTRAINDICATIONS:
The DETOURTM System is contraindicated in patients with:

A distal common femoral artery (CFA) <7 mm in diameter.
Increased risk of deep vein thrombosis (DVT), such as patients with a recent history of DVT, thrombophilia, and disseminated malignancy.
Untreated flow-limiting aortoiliac occlusive disease.
Lack of patent single vessel tibial runoff to ankle.
Known coagulopathy, bleeding diathesis, or thrombocytopenia that cannot be medically managed.
Known hypersensitivities, allergies or contraindications to: Nitinol; PTFE; aspirin; heparin; antiplatelet; anticoagulant or thrombolytic therapy; or contrast media that cannot otherwise be medically managed.

Refer to Instructions for Use for more information concerning Indications, Contraindications, Specific Anatomic Considerations, Warnings, Precautions, and Adverse Events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

NOTE: Not all product components are available in every country.

Please consult with your Endologix representative to confirm product availability.

Endologix^® is a registered trademark of Endologix LLC in the United States, Europe and Japan. All other trademarks are the property of their respective owners.

DETOUR Embrace the Evidence

Embrace the evidence.